Giandomenico Turchiano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giandomenico Turchiano has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
Marianna Romito
Infection, Immunity, and Inflammation Teaching and Research Department, Great Ormond Street Institute of Child Health, University College London, London, United Kingdom
4 shared publications- Adrian James Thrasher
Infection, Immunity, and Inflammation Teaching and Research Department, Great Ormond Street Institute of Child Health, University College London, London, United Kingdom
3 shared publications Alessia Cavazza
Infection, Immunity, and Inflammation Teaching and Research Department, Great Ormond Street Institute of Child Health, University College London , London, WC1N 1DZ
3 shared publications- Toni Cathomen
Medical Center - University of Freiburg
3 shared publications Yi-Ting Hu
Infection, Immunity, and Inflammation Teaching and Research Department, Great Ormond Street Institute of Child Health, University College London , London, WC1N 1DZ
3 shared publications- Alessia Cavazza
Molecular and Cellular Immunology Section, Department of Infection, Immunity & Inflammation, Great Ormond Street Institute of Child Health, University College London, London WC1N 1DZ, UK
2 shared publications
Latest Publications
- Open Access
Sensitive Chromosomal Translocation Quantitation from Amplicon Sequencing Using Primer-Anchored Statistical Translocation Analysis (PASTA)
Chromosomal translocations are rare structural rearrangement outcomes of genome editing, requiring analytical frameworks that combine high quantitative accuracy with performant sensitivity and specificity. Amplicon sequencing offers a scalable means to detect rare rearrangements with ultra-deep targeted sequencing, but existing methods often rely on heuristic thresholds or ad hoc normalization steps that limit reproducibility and have unknown analytical performance. Here, we present a computational tool we call PASTA (Primer-Anchored Statistical Translocation Analysis), using a count-based differential-event statistical framework to quantify and statistically confirm translocation junctions from targeted amplicon sequencing data. Comparison of this method to ddPCR demonstrates that quantitation is highly accurate, and outperforms other NGS-based methods even when randomized adapter chemistry is not present in amplicon sequencing structures. To measure analytical performance, we create a benchmarking dataset for measuring chromosomal translocation analysis performance with frequencies ranging from 1% to sub-0.01%, and demonstrate that the method can detect frequencies down to 0.01% with >75% sensitivity when sufficient read depth is present. Taken together, this work demonstrates using amplicon sequencing with PASTA as a bioinformatics analysis tool is a solution for translocation detection in amplicon sequencing genotoxicity assessments, enabling identification of rare genome rearrangements in both research and preclinical applications
Open AccessSensitive Chromosomal Translocation Quantitation from Amplicon Sequencing Using Primer-Anchored Statistical Translocation Analysis (PASTA)
Chromosomal translocations are rare structural rearrangement outcomes of genome editing, requiring analytical frameworks that combine high quantitative accuracy with performant sensitivity and specificity. Amplicon sequencing offers a scalable means to detect rare rearrangements with ultra-deep targeted sequencing, but existing methods often rely on heuristic thresholds or ad hoc normalization steps that limit reproducibility and have unknown analytical performance. Here, we present a computational tool we call PASTA (Primer-Anchored Statistical Translocation Analysis), using a count-based differential-event statistical framework to quantify and statistically confirm translocation junctions from targeted amplicon sequencing data. Comparison of this method to ddPCR demonstrates that quantitation is highly accurate, and outperforms other NGS-based methods even when randomized adapter chemistry is not present in amplicon sequencing structures. To measure analytical performance, we create a benchmarking dataset for measuring chromosomal translocation analysis performance with frequencies ranging from 1% to sub-0.01%, and demonstrate that the method can detect frequencies down to 0.01% with >75% sensitivity when sufficient read depth is present. Taken together, this work demonstrates using amplicon sequencing with PASTA as a bioinformatics analysis tool is a solution for translocation detection in amplicon sequencing genotoxicity assessments, enabling identification of rare genome rearrangements in both research and preclinical applications
- Open Access
- 19 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 5074
Safety and efficacy analysis of in vivo lentiviral gene therapy in pre-clinical ARC syndrome models
Arthrogryposis, Renal dysfunction and Cholestasis (ARC) syndrome is a rare inherited disorder caused by defects in the VPS33B trafficking protein, leading to impaired bile flow, progressive liver disease and early death. No effective treatments are currently available. Gene therapy offers a potential approach by restoring the missing VPS33B protein in liver cells. Here, we show that liver-targeted lentiviral gene therapy safely and effectively rescues key features of ARC syndrome in a mouse model following in vivo administration by intravenous injection, combined with transient liver macrophage depletion. To assess the treatment efficacy, disease severity is exacerbated by 0.25% cholic acid diet feeds. A liver-specific vector shows a favourable safety profile over a ubiquitous vector. Mice receiving the safe liver-specific vector display improved survival, growth and liver function, reduced fibrosis and bile canaliculi restoration. These findings support targeted gene therapy as a promising treatment for ARC syndrome and related early-onset liver diseases.
- 19 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 5074
Open AccessSafety and efficacy analysis of in vivo lentiviral gene therapy in pre-clinical ARC syndrome models
Arthrogryposis, Renal dysfunction and Cholestasis (ARC) syndrome is a rare inherited disorder caused by defects in the VPS33B trafficking protein, leading to impaired bile flow, progressive liver disease and early death. No effective treatments are currently available. Gene therapy offers a potential approach by restoring the missing VPS33B protein in liver cells. Here, we show that liver-targeted lentiviral gene therapy safely and effectively rescues key features of ARC syndrome in a mouse model following in vivo administration by intravenous injection, combined with transient liver macrophage depletion. To assess the treatment efficacy, disease severity is exacerbated by 0.25% cholic acid diet feeds. A liver-specific vector shows a favourable safety profile over a ubiquitous vector. Mice receiving the safe liver-specific vector display improved survival, growth and liver function, reduced fibrosis and bile canaliculi restoration. These findings support targeted gene therapy as a promising treatment for ARC syndrome and related early-onset liver diseases.
- Open Access
- 13 April 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (7)
DNA-PKcs inhibitor AZD7648 reveals sgRNA cross-contaminants and enhanced sensitivity of genome engineering off-target activity in HSPCs
Therapeutic gene editing with designer nucleases can be compromised by undesired repair outcomes. DNA repair inhibitors are used to bias DSB repair toward HDR, but their impact on larger structural rearrangements, including large deletions and translocations, remains unclear. We quantify the mutational burden associated with end-joining inhibitor compounds. With a highly precise Cas9 nuclease, repair inhibition yields modest increases in aberrations, whereas promiscuous single guide RNAs (sgRNAs) amplify aberrant outcomes by orders of magnitude. Donor templates mitigate mutational burden at on-target sites, and in rare cases donor sequences bridge translocations between on- and off-target loci. Because DNA-PKcs inhibition does not itself induce instability over short intervals but increases the likelihood of capturing chromosomal aberrations postediting, we leveraged this to enhance assay performance. Compared to CAST-Seq, high-resolution CAST-Seq achieved a median ~12-fold increase in detected aberrations and, in this higher-sensitivity context, revealed unintended, target-specific sgRNA contaminants in GMP-like batches, underscoring direct genotoxicity risk and the need for stricter guide purity controls. A modified, translocation-quantitative rhAmpSeq reports all translocation combinations between two loci, enabling robust off-target validation beyond indel-only readouts. Finally, we evaluate AZD7648, finding limited aberration increases with precise nucleases and reconciling reports of extensive large deletions by quantifying assay- and design-dependent biases.
- 13 April 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (7)
Open AccessDNA-PKcs inhibitor AZD7648 reveals sgRNA cross-contaminants and enhanced sensitivity of genome engineering off-target activity in HSPCs
Therapeutic gene editing with designer nucleases can be compromised by undesired repair outcomes. DNA repair inhibitors are used to bias DSB repair toward HDR, but their impact on larger structural rearrangements, including large deletions and translocations, remains unclear. We quantify the mutational burden associated with end-joining inhibitor compounds. With a highly precise Cas9 nuclease, repair inhibition yields modest increases in aberrations, whereas promiscuous single guide RNAs (sgRNAs) amplify aberrant outcomes by orders of magnitude. Donor templates mitigate mutational burden at on-target sites, and in rare cases donor sequences bridge translocations between on- and off-target loci. Because DNA-PKcs inhibition does not itself induce instability over short intervals but increases the likelihood of capturing chromosomal aberrations postediting, we leveraged this to enhance assay performance. Compared to CAST-Seq, high-resolution CAST-Seq achieved a median ~12-fold increase in detected aberrations and, in this higher-sensitivity context, revealed unintended, target-specific sgRNA contaminants in GMP-like batches, underscoring direct genotoxicity risk and the need for stricter guide purity controls. A modified, translocation-quantitative rhAmpSeq reports all translocation combinations between two loci, enabling robust off-target validation beyond indel-only readouts. Finally, we evaluate AZD7648, finding limited aberration increases with precise nucleases and reconciling reports of extensive large deletions by quantifying assay- and design-dependent biases.
- Open Access
- 3 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Unveiling the cut-and-repair cycle of designer nucleases in human stem and T cells via CLEAR-time dPCR
DNA repair mechanisms in human primary cells, including error-free repair, and, recurrent nuclease cleavage events, remain largely uncharacterised. We elucidate gene-editing related repair processes using Cleavage and Lesion Evaluation via Absolute Real-time dPCR (CLEAR-time dPCR), an ensemble of multiplexed dPCR assays that quantifies genome integrity at targeted sites. Utilising CLEAR-time dPCR we track active DSBs, small indels, large deletions, and other aberrations in absolute terms in clinically relevant edited cells, including HSPCs, iPSCs, and T-cells. By quantifying up to 90% of loci with unresolved DSBs, CLEAR-time dPCR reveals biases inherent to conventional mutation screening assays. Furthermore, we accurately quantify DNA repair precision, revealing prevalent scarless repair after blunt and staggered end DSBs and recurrent nucleases cleavage. This work provides one of the most precise analyses of DNA repair and mutation dynamics, paving the way for mechanistic studies to advance gene therapy, designer editors, and small molecule discovery.
- 3 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Open AccessUnveiling the cut-and-repair cycle of designer nucleases in human stem and T cells via CLEAR-time dPCR
DNA repair mechanisms in human primary cells, including error-free repair, and, recurrent nuclease cleavage events, remain largely uncharacterised. We elucidate gene-editing related repair processes using Cleavage and Lesion Evaluation via Absolute Real-time dPCR (CLEAR-time dPCR), an ensemble of multiplexed dPCR assays that quantifies genome integrity at targeted sites. Utilising CLEAR-time dPCR we track active DSBs, small indels, large deletions, and other aberrations in absolute terms in clinically relevant edited cells, including HSPCs, iPSCs, and T-cells. By quantifying up to 90% of loci with unresolved DSBs, CLEAR-time dPCR reveals biases inherent to conventional mutation screening assays. Furthermore, we accurately quantify DNA repair precision, revealing prevalent scarless repair after blunt and staggered end DSBs and recurrent nucleases cleavage. This work provides one of the most precise analyses of DNA repair and mutation dynamics, paving the way for mechanistic studies to advance gene therapy, designer editors, and small molecule discovery.
- Top Cited PapersOpen Access
- 17 July 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (3) , 102636
Off-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges
- 17 July 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (3) , 102636
Top Cited PapersOpen AccessOff-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges
- Open Access
- 26 June 2024
- Published by Springer Nature in Research Square
MEGA dPCR reveals chromosomal aberrations, NHEJ precise repair, recurrent nuclease cleavage and DSB half-life
Advances in designer DNA editors, such as programmable nucleases, PASTE, Prime, and base editors, have recently proved their therapeutic value and potential to treat genetic disorders. However, a comprehensive understanding of their cellular activities is essential for improving their editing efficiency and ensuring a safe clinical translation of cell and gene therapies. A myriad of techniques have emerged to detect or anticipate genotoxic events, reflecting the increasing demand for a thorough characterisation over these editing tools’ activities. Nonetheless, these approaches have limitations, including high costs, time-consuming procedures, requirement of extensive bioinformatics knowledge, and the inference of selective and sometimes biased aberration evaluation. Moreover, the temporal dynamics of DNA editing and subsequent repairs remain poorly understood, permitting misinterpretation as well as observational biases. To address these challenges, we introduce Multipurpose Editing and Genotoxicity Assessment (MEGA), a novel diagnostic toolkit employing multiplexed digital PCR (dPCR) assays for a comprehensive characterisation of mutations arising alongside the on- and off-target sites by gene editing tools. MEGA delivers valuable insights into genome integrity as well as quantification of episomal or integrated DNA donor templates. To demonstrate the widespread applicability of MEGA, we used numerous designer nucleases (SpCas9, TALEN, Cas12a, and PsCas9) to edit clinically relevant primary cells, including human haematopoietic stem and progenitor cells (HSPCs) pre- and post-transplantation in murine model, induced pluripotent stem cells (iPSCs), and T cells. By quantifying up to ~90% of alleles with unresolved double-strand breaks (DSBs) and other aberrations across various therapeutic gene targets, we exposed the biases of commonly used mutation-screening assays. MEGA’s unmatched characterisation in assessing DNA status post-editing revealed many novel insights into DNA repair inhibitor effects, designer nuclease activity and DNA repair mechanisms in primary cells, including the elusive yet highly prevalent precise DSB repair via NHEJ and subsequent recurrent nuclease cleavage events. This technology also enabled us to measure the mutation probabilities of DSB resolution with unprecedented accuracy, as well as expose the kinetics associated with their resolution by DNA repair pathways. MEGA addresses critical gaps in the available genetic engineering analysis toolkit by providing a rapid, accessible, and specific overview of genome integrity post-gene editing that can be effortlessly applied to clinically relevant samples. Furthermore, by exploiting this novel technique, we elucidated fundamental biological concepts underlying DNA repair, paving the way for extensive mechanistic studies for improving designer editor activity and gene therapy safety.
- 26 June 2024
- Published by Springer Nature in Research Square
Open AccessMEGA dPCR reveals chromosomal aberrations, NHEJ precise repair, recurrent nuclease cleavage and DSB half-life
Advances in designer DNA editors, such as programmable nucleases, PASTE, Prime, and base editors, have recently proved their therapeutic value and potential to treat genetic disorders. However, a comprehensive understanding of their cellular activities is essential for improving their editing efficiency and ensuring a safe clinical translation of cell and gene therapies. A myriad of techniques have emerged to detect or anticipate genotoxic events, reflecting the increasing demand for a thorough characterisation over these editing tools’ activities. Nonetheless, these approaches have limitations, including high costs, time-consuming procedures, requirement of extensive bioinformatics knowledge, and the inference of selective and sometimes biased aberration evaluation. Moreover, the temporal dynamics of DNA editing and subsequent repairs remain poorly understood, permitting misinterpretation as well as observational biases. To address these challenges, we introduce Multipurpose Editing and Genotoxicity Assessment (MEGA), a novel diagnostic toolkit employing multiplexed digital PCR (dPCR) assays for a comprehensive characterisation of mutations arising alongside the on- and off-target sites by gene editing tools. MEGA delivers valuable insights into genome integrity as well as quantification of episomal or integrated DNA donor templates. To demonstrate the widespread applicability of MEGA, we used numerous designer nucleases (SpCas9, TALEN, Cas12a, and PsCas9) to edit clinically relevant primary cells, including human haematopoietic stem and progenitor cells (HSPCs) pre- and post-transplantation in murine model, induced pluripotent stem cells (iPSCs), and T cells. By quantifying up to ~90% of alleles with unresolved double-strand breaks (DSBs) and other aberrations across various therapeutic gene targets, we exposed the biases of commonly used mutation-screening assays. MEGA’s unmatched characterisation in assessing DNA status post-editing revealed many novel insights into DNA repair inhibitor effects, designer nuclease activity and DNA repair mechanisms in primary cells, including the elusive yet highly prevalent precise DSB repair via NHEJ and subsequent recurrent nuclease cleavage events. This technology also enabled us to measure the mutation probabilities of DSB resolution with unprecedented accuracy, as well as expose the kinetics associated with their resolution by DNA repair pathways. MEGA addresses critical gaps in the available genetic engineering analysis toolkit by providing a rapid, accessible, and specific overview of genome integrity post-gene editing that can be effortlessly applied to clinically relevant samples. Furthermore, by exploiting this novel technique, we elucidated fundamental biological concepts underlying DNA repair, paving the way for extensive mechanistic studies for improving designer editor activity and gene therapy safety.
- 16 April 2024
- Published by SAGE Publications in Human Gene Therapy
- Vol. 35 (7-8) , 269-283
CRISPR/Cas9-Based Disease Modeling and Functional Correction of Interleukin 7 Receptor Alpha Severe Combined Immunodeficiency in T-Lymphocytes and Hematopoietic Stem Cells
Interleukin 7 Receptor alpha Severe Combined Immunodeficiency (IL7R-SCID) is a life-threatening disorder caused by homozygous mutations in the IL7RA gene. Defective IL7R expression in humans hampers T cell precursors' proliferation and differentiation during lymphopoiesis resulting in the absence of T cells in newborns, who succumb to severe infections and death early after birth. Previous attempts to tackle IL7R-SCID by viral gene therapy have shown that unregulated IL7R expression predisposes to leukemia, suggesting the application of targeted gene editing to insert a correct copy of the IL7RA gene in its genomic locus and mediate its physiological expression as a more feasible therapeutic approach. To this aim, we have first developed a CRISPR/Cas9-based IL7R-SCID disease modeling system that recapitulates the disease phenotype in primary human T cells and hematopoietic stem and progenitor cells (HSPCs). Then, we have designed a knockin strategy that targets IL7RA exon 1 and introduces through homology-directed repair a corrective, promoterless IL7RA cDNA followed by a reporter cassette through AAV6 transduction. Targeted integration of the corrective cassette in primary T cells restored IL7R expression and rescued functional downstream IL7R signaling. When applied to HSPCs further induced to differentiate into T cells in an Artificial Thymic Organoid system, our gene editing strategy overcame the T cell developmental block observed in IL7R-SCID patients, while promoting full maturation of T cells with physiological and developmentally regulated IL7R expression. Finally, genotoxicity assessment of the CRISPR/Cas9 platform in HSPCs using biased and unbiased technologies confirmed the safety of the strategy, paving the way for a new, efficient, and safe therapeutic option for IL7R-SCID patients.
- 16 April 2024
- Published by SAGE Publications in Human Gene Therapy
- Vol. 35 (7-8) , 269-283
CRISPR/Cas9-Based Disease Modeling and Functional Correction of Interleukin 7 Receptor Alpha Severe Combined Immunodeficiency in T-Lymphocytes and Hematopoietic Stem Cells
Interleukin 7 Receptor alpha Severe Combined Immunodeficiency (IL7R-SCID) is a life-threatening disorder caused by homozygous mutations in the IL7RA gene. Defective IL7R expression in humans hampers T cell precursors' proliferation and differentiation during lymphopoiesis resulting in the absence of T cells in newborns, who succumb to severe infections and death early after birth. Previous attempts to tackle IL7R-SCID by viral gene therapy have shown that unregulated IL7R expression predisposes to leukemia, suggesting the application of targeted gene editing to insert a correct copy of the IL7RA gene in its genomic locus and mediate its physiological expression as a more feasible therapeutic approach. To this aim, we have first developed a CRISPR/Cas9-based IL7R-SCID disease modeling system that recapitulates the disease phenotype in primary human T cells and hematopoietic stem and progenitor cells (HSPCs). Then, we have designed a knockin strategy that targets IL7RA exon 1 and introduces through homology-directed repair a corrective, promoterless IL7RA cDNA followed by a reporter cassette through AAV6 transduction. Targeted integration of the corrective cassette in primary T cells restored IL7R expression and rescued functional downstream IL7R signaling. When applied to HSPCs further induced to differentiate into T cells in an Artificial Thymic Organoid system, our gene editing strategy overcame the T cell developmental block observed in IL7R-SCID patients, while promoting full maturation of T cells with physiological and developmentally regulated IL7R expression. Finally, genotoxicity assessment of the CRISPR/Cas9 platform in HSPCs using biased and unbiased technologies confirmed the safety of the strategy, paving the way for a new, efficient, and safe therapeutic option for IL7R-SCID patients.
- Top Cited Papers
- 1 June 2021
- Published by Elsevier in Cell Stem Cell
- Vol. 28 (6) , 1136-1147.e5
Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq
- 1 June 2021
- Published by Elsevier in Cell Stem Cell
- Vol. 28 (6) , 1136-1147.e5
Top Cited PapersQuantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq
- Open Access
- 10 December 2020
- Published by Frontiers Media SA in Frontiers in Genome Editing
- Vol. 2
Gene Editing and Genotoxicity: Targeting the Off-Targets
Gene editing technologies show great promise for application to human disease as a result of rapid developments in targeting tools notably based on ZFN, TALEN, and CRISPR-Cas systems. Precise modification of a DNA sequence is now possible in mature human somatic cells including stem and progenitor cells with increasing degrees of efficiency. At the same time new technologies are required to evaluate their safety and genotoxicity before widespread clinical application can be confidently implemented. A number of methodologies have now been developed in an attempt to predict expected and unexpected modifications occurring during gene editing. This review surveys the techniques currently available as state of the art, highlighting benefits and limitations, and discusses approaches that may achieve sufficient accuracy and predictability for application in clinical settings.
- 10 December 2020
- Published by Frontiers Media SA in Frontiers in Genome Editing
- Vol. 2
Open AccessGene Editing and Genotoxicity: Targeting the Off-Targets
Gene editing technologies show great promise for application to human disease as a result of rapid developments in targeting tools notably based on ZFN, TALEN, and CRISPR-Cas systems. Precise modification of a DNA sequence is now possible in mature human somatic cells including stem and progenitor cells with increasing degrees of efficiency. At the same time new technologies are required to evaluate their safety and genotoxicity before widespread clinical application can be confidently implemented. A number of methodologies have now been developed in an attempt to predict expected and unexpected modifications occurring during gene editing. This review surveys the techniques currently available as state of the art, highlighting benefits and limitations, and discusses approaches that may achieve sufficient accuracy and predictability for application in clinical settings.
- 1 April 2017
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 137 (4) , 836-844
Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes
- 1 April 2017
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 137 (4) , 836-844
Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes